Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer.
Chatterjee SS, Linares JF, Cid-Diaz T, Duran A, Khan MIK, Osrodek M, Brady NJ, Reina-Campos M, Marzio A, Venkadakrishnan VB, Bakht MK, Khani F, Mosquera JM, Robinson BD, Moyer J, Elemento O, Hsieh AC, Goodrich DW, Rickman DS, Beltran H, Moscat J, Diaz-Meco MT.
Chatterjee SS, et al. Among authors: duran a.
Nat Commun. 2024 Nov 20;15(1):9755. doi: 10.1038/s41467-024-53874-2.
Nat Commun. 2024.
PMID: 39567499
Free PMC article.